Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis – the importance of structured causality assessment: A case report (2026)

Peer-Reviewed Study · Krishnan A, Lucas K, Maas L, Woreta TA · 2026

Krishnan A et al., 2026: A 47-year-old woman with metastatic colon cancer on nivolumab/relatlimab developed severe hepatocellular injury after raising her self-administered fenbendazole dose; RUCAM scored 8 (probable) and the injury resolved after stopping fenbendazole while immunotherapy continued safely.

We report a case of a 47-year-old woman with metastatic colon cancer on nivolumab/relatlimab who developed severe hepatocellular liver injury after increasing her self-administered dose of fenbendazole.

Krishnan A et al., 2026: A 47-year-old woman with metastatic colon cancer on nivolumab/relatlimab developed severe hepatocellular injury after raising her self-administered fenbendazole dose; RUCAM scored 8 (probable) and the injury resolved after stopping fenbendazole while immunotherapy continued safely. C8. Study type: case report; N=1; country USA (Johns Hopkins); self-administered fenbendazole with a dose increase (numbers in full text); concurrent nivolumab/relatlimab; funder/conflicts not stated in abstract; maker not stated. Notable because the causality method separates fenbendazole from immunotherapy hepatitis – the distinction the book's 'no monitoring' advice would blur. Also filed as FBE-29 (claims C3, C8). Study type: case report.